Figure S4 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer

figure

posted on 2023-04-04, 01:46 authored by Ryon P. Graf, Virginia Fisher, James Creeden, Alexa B. Schrock, Jeffrey S. Ross, Halla Nimeiri, Geoffrey R. Oxnard, Samuel J. Klempner

Unadjusted for known treatment assignment imbalances, patients receiving 2nd line ICPI vs. chemotherapy have more favorable outcomes when TMB ≥ 10 but not TMB < 10. Kaplan-Meier curves are unadjusted for imbalances. TTNT is shown by drug class for (A) TMB < 10, and (B) TMB ≥ 10. OS is shown by drug class for (C) TMB < 10, and (D) TMB ≥ 10. X-axis is truncated at 36 months. Overall survival estimates are left truncated (see Methods) with at-risk tables adjusted accordingly. Interaction models can be found in Supplemental Figure 8.

Funding

AGA Research Foundation (American Gastroenterological Association (AGA) Research Foundation)

History

ARTICLE ABSTRACT

Using real-world data, we sought to evaluate robustness of these clinical associations using the same assay platform and biomarker cut-off point used in both clinical trials and pan-tumor CDx approvals for later treatment lines. TMB ≥ 10 robustly identified patients with mEG with more favorable outcomes on ICPI monotherapy versus chemotherapy and suggests this subset of patients could be targeted for further trial development.

Usage metrics

Keywords

Gastrointestinal Cancers Esophageal cancer Stomach cancer Biomarkers Genetic biomarkers Immunotherapy Checkpoint blockade Biomarkers for immunotherapy Precision Medicine

Licence

CC BY